行情

AGIO

AGIO

Agios制药
NASDAQ

实时行情|Nasdaq Last Sale

53.13
+0.57
+1.08%
交易中 14:25 01/29 EST
开盘
52.58
昨收
52.56
最高
53.22
最低
52.23
成交量
14.60万
成交额
--
52周最高
68.94
52周最低
28.36
市值
35.66亿
市盈率(TTM)
-7.7605
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGIO 新闻

  • 欧洲议会表决通过“脱欧”协议 为英国脱欧铺平道路
  • 新浪财经.1小时前
  • 美国12月份二手房签约量录得2010年以来最大降幅
  • 新浪财经.2小时前
  • 午盘:联储决议在即 美股维持涨势
  • 新浪美股.2小时前
  • 冠状病毒阴云笼罩 苹果公司“复苏”之路前景存疑
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
-0.06%
制药与医学研究
+0.39%

热门股票

名称
价格
涨跌幅

AGIO 简况

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
展开

Webull提供Agios Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。